These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35417040)

  • 1. Multifaceted targeted protein degradation systems for different cellular compartments.
    Zorca CE; Fallahi A; Luo S; Eldeeb MA
    Bioessays; 2022 Jun; 44(6):e2200008. PubMed ID: 35417040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
    Alabi SB; Crews CM
    J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Protein Degradation via Lysosomes.
    Paudel RR; Lu D; Roy Chowdhury S; Monroy EY; Wang J
    Biochemistry; 2023 Feb; 62(3):564-579. PubMed ID: 36130224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes.
    Venkatesan J; Murugan D; Lakshminarayanan K; Smith AR; Vasanthakumari Thirumalaiswamy H; Kandhasamy H; Zender B; Zheng G; Rangasamy L
    Pharmacol Ther; 2024 Nov; 263():108725. PubMed ID: 39322067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted protein degradation in drug development: Recent advances and future challenges.
    Song J; Hu M; Zhou J; Xie S; Li T; Li Y
    Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing targeted protein degradation for metabolic diseases therapy.
    Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
    Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions.
    Kamaraj R; Ghosh S; Das S; Sen S; Kumar P; Majumdar M; Dasgupta R; Mukherjee S; Das S; Ghose I; Pavek P; Raja Karuppiah MP; Chuturgoon AA; Anand K
    Bioconjug Chem; 2024 Aug; 35(8):1089-1115. PubMed ID: 38990186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway.
    Cassidy K; Zhao H
    Biochemistry; 2023 Feb; 62(3):580-587. PubMed ID: 34569233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design.
    Chen Y; Liu F; Pal S; Hu Q
    Chem Soc Rev; 2024 Sep; 53(19):9582-9608. PubMed ID: 39171633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in targeted protein degraders as potential therapeutic agents.
    Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
    Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy.
    Fang Y; Wang J; Zhao M; Zheng Q; Ren C; Wang Y; Zhang J
    J Med Chem; 2022 Sep; 65(17):11454-11477. PubMed ID: 36006861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
    Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
    Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.
    Lin J; Jin J; Shen Y; Zhang L; Gong G; Bian H; Chen H; Nagle DG; Wu Y; Zhang W; Luan X
    Theranostics; 2021; 11(17):8337-8349. PubMed ID: 34373745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted protein degradation directly engaging lysosomes or proteasomes.
    Kim J; Byun I; Kim DY; Joh H; Kim HJ; Lee MJ
    Chem Soc Rev; 2024 Apr; 53(7):3253-3272. PubMed ID: 38369971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging degrader technologies engaging lysosomal pathways.
    Ding Y; Xing D; Fei Y; Lu B
    Chem Soc Rev; 2022 Oct; 51(21):8832-8876. PubMed ID: 36218065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
    Coll-Martínez B; Delgado A; Crosas B
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring the Overall Rate of Protein Breakdown in Cells and the Contributions of the Ubiquitin-Proteasome and Autophagy-Lysosomal Pathways.
    Sha Z; Zhao J; Goldberg AL
    Methods Mol Biol; 2018; 1844():261-276. PubMed ID: 30242715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications].
    Reboud-Ravaux M
    Biol Aujourdhui; 2024; 218(1-2):41-54. PubMed ID: 39007776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy mediated targeting degradation, a promising strategy in drug development.
    Zhang J; Pan X; Ji W; Zhou J
    Bioorg Chem; 2024 Aug; 149():107466. PubMed ID: 38843684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.